In another study, plerixafor, a CXCR4 antagonist, disengaged CML cells from bone marrow stroma and extracellular matrix and made them vulnerable to nilotinib therapy [79]. The gene discussed is CXCR4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.